Economy Pluristem changes the game with strong preliminary COVID 19...

Pluristem changes the game with strong preliminary COVID 19 results; Analyst says “buy”

-

With the war against COVID-19, Wall Street focused on the names on the front. To fight a formidable enemy that can spread without a trace, innovative technologies are needed to arm the world’s population. As such, market watchers stand by and hope to identify the health care companies that can deliver effective weapons against the deadly virus.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Pluristem Therapeutics (PSTI) has a chance to fight. On April 7, the company reported that its treatment for acute respiratory failure and inflammatory complications caused by COVID-19 had shown robust preliminary results from the compassionate use program and response rates were 21% higher. In March, the Israeli Ministry of Health approved PLX cell treatment, which uses allogeneic mesenchymal cells with immunomodulatory properties, for the treatment of severe COVID-19 patients per patient. Therapy should prevent or even reverse the harmful over-activation of the immune system. “Data-reactid =” 13 “> Pluristem Therapeutics (PSTI) has a chance to fight. On April 7, the company reported that its treatment for acute respiratory failure and inflammatory complications caused by COVID-19 had shown robust preliminary results from the compassionate use program and response rates were 21% higher. In March, the Israeli Ministry of Health approved PLX cell treatment, which uses allogeneic mesenchymal cells with immunomodulatory properties, for the treatment of severe COVID-19 patients per patient. Therapy should prevent or even reverse the harmful over-activation of the immune system.

The results were promising to say the least. Management indicated that seven patients in the intensive care unit had been treated for acute respiratory distress syndrome (ARDS). All patients are alive, which means the survival rate is 100% and six out of seven patients have been followed up for at least a week. In addition, four patients showed improvement in breathing parameters, one remained stable, and only one showed deterioration. Three are also in the advanced stage of ventilator removal.

Weighing for H.C. Wainwright, analyst Swayampakula Ramakanth, called the early data “encouraging” and believes that the treatment could lead to significant gains for PSTI. The next step is a regulated and multinational clinical trial.

“We believe that the ongoing pandemic in almost all countries and the strain on health systems around the world urgently require new, effective treatments. We therefore believe that both the FDA and the EMA can accelerate approval for clinical trials and only the future regulatory pathways. We believe the company can complete the first trials and report the results in 2H20 because regulatory convenience and patients only need a 28-day follow-up, ”said Ramakanth.

<p class = "Canvas Atom Canvas Text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "In accordance with this optimistic attitude, Ramakanth left a Shop The stock has a rating of $ 15.50 and the upside potential is a whopping 277%. (To see Ramakanth's track record, click here) “data-reactid =” 17 “> In line with this optimistic outlook, Ramakanth has given the share a buy rating. At $ 15.50, the upside potential is a whopping 277%. (To see Ramakanth’s track record, click here)

As with other analyst activities, PSTI was relatively quiet. Only one other call has recently been released, but it was also optimistic, making analyst consensus a moderate buy. The average price target of $ 11.75 is less aggressive than that of Ramakanth and implies an upside potential of 173%. (See Pluristem stock analysis at TipRanks)

<p class = "Artboard-Atom Artboard-Text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "To find good ideas for trading healthcare stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all the insights into TipRanks stocks.“data-reactid =” 27 “>To find good ideas for trading healthcare stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all the insights into TipRanks stocks.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Latest news

Infinite monetary emission and discriminatory inflation: where and when?

The counter of the monetary issue by the Federal Reserve of the United States is measured by the...

Alcohol and BBQ allowed in 22 Quebec parks as of Friday

From Friday, it will be legal to...

Our stools could help prevent a second wave

Researchers around the world are investigating the...

Must read

You might also likeRELATED
Recommended to you